A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Merck Sharp & Dohme LLC0 个研究点目标入组 735 人开始时间: 2019年4月17日最近更新: 2024年5月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Merck Sharp & Dohme LLC
入组人数: 735

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Have a histologically or cytologically confirmed diagnosis squamous NSCLC. Patients with mixed histology (eg, adenosquamous) are allowed if there is squamous component in the specimen
•- Have stage IV (T any, N any, M1a, M1b, or M1c as per AJCC 8th edition) squamous NSCLC
•- Have measurable disease based on RECIST 1.1, as determined by the local site investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
•- Have not received prior systemic treatment for their advanced/metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease
•- Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
•- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention
•- Have a life expectancy of at least 3 months
•- Has adequate organ function; all screening laboratory tests should be performed within 10 days prior to initiation of study treatment
•- Be =18 years of age on day of signing informed consent
•- Male participants are eligible to participate if they agree to the following during the intervention period for at least 180 days after the
•last dose of study intervention:
•Refrain from donating sperm
•Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree
•to remain abstinent
•Agree to use contraception, unless confirmed to be azoospermic (vasectomized or secondary to medical cause [Appendix 5]), as detailed
•Agree to use male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a
•woman of childbearing potential (WOCBP) who is not currently pregnant.
•Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom
•during each episode of penile-vaginal penetration.
•- A female participant is eligible to participate if she is not pregnant (Appendix 5), not breastfeeding, and at least 1 of the following
•conditions applies:
•a. Not a woman of childbearing potential (WOCBP).
•b. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 180 days following the last dose of
•pembrolizumab and olaparib or at least 180 days following the last dose of cytotoxic chemotherapy and agrees not to donate eggs (ova, oocytes)
•to others or freeze/store for her own use for the purpose of reproduction during this period. A WOCBP must have a negative highly sensitive urine
•pregnancy test as required by local regulations) within 24 hours (72 hours for serum) before the first dose of study intervention.
•- Has (or legally acceptable representative if applicable) provided written informed consent/assent for the study. The participant may also provide consent/assent for Future Biomedical Research. However, the participant may participate in the main trial without participating in Future Biomedical Research
•- Has a CR/PR or stable disease of their

排除标准

•- Non-squamous histology NSCLC
•- Additional malignancy progressing or progressed within the past 3 years requiring active treatment
•- Central nervous system (CNS) metastases and/or carcinomatous meningitis.
•Participants with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks and, have no evidence of new or enlarging brain metastases, and also are off steroids 3 days prior to dosing with study medication
•- Autoimmune disease that has required systemic treatment in the past 2 years
•- Immunodeficiency or receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or other immunosuppressive therapy within 7 days prior to first dose
•- History of (noninfectious) pneumonitis requiring systemic steroids, interstitial lung disease
•- Known history of active tuberculosis, HIV infection, HBV infection, or active HCV infection
•- Current pneumonitis
•- Prior treatment with olaparib or any other PARP inhibitor
•- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or agent directed to another stimulatory or co-inhibitory T cell receptor
•- Prior systemic chemotherapy or other targeted or biological antineoplastic therapy for metastatic disease
•- Receiving either strong or moderate inducers or inhibitor of CYP3A4 that cannot be discontinued for the duration of the study

研究者

发起方

Merck Sharp & Dohme LLC

相似试验

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-004720-11-ATMerck Sharp & Dohme LLC1,005

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-004720-11-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.792

进行中（未招募）

1 期

EUCTR2018-004720-11-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,792

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in 1L ES SCLCExtensive Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-004843-22-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc699

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

CTIS2023-509774-40-00Merck Sharp & Dohme LLC672